1-5 of 5
Julian Andreev
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Andres E. Perez Bay, Devon Faulkner, John O. DaSilva, Tara M. Young, Katie Yang, Jason T. Giurleo, Dangshe Ma, Frank J. Delfino, William C. Olson, Gavin Thurston, Christopher Daly, Julian Andreev
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (3): 357–370.
https://doi.org/10.1158/1535-7163.MCT-22-0414
Published: 02 March 2023
View article titled, A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Open the PDF for A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers

Marcus P. Kelly, Carlos Hickey, Sosina Makonnen, Sandra Coetzee, Sumreen Jalal, Yu Wang, Frank Delfino, Jing Shan, Terra B. Potocky, Ishita Chatterjee, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason T. Giurleo, Thomas Nittoli, Pamela A. Trail, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1299–1311.
https://doi.org/10.1158/1535-7163.MCT-16-0839
Published: 04 July 2017
View article titled, Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Open the PDF for Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data
Journal Articles

Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)

Julian Andreev, NIthya Thambi, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Douglas MacDonald, Nicholas Popadopoulos, Willian Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A131.
https://doi.org/10.1158/1535-7163.TARG-15-A131
Published: 01 December 2015
View article titled, Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)
Journal Articles

Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer

Marcus P. Kelly, Sandra Coetzee, Carlos Hickey, Sosina Makonnen, Frank Delfino, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason Giurleo, Thomas Nittoli, Pamela A. Trail, Nicholas Papadopoulos, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C126.
https://doi.org/10.1158/1535-7163.TARG-15-C126
Published: 01 December 2015
View article titled, Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer